Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Diabetes Mellitus
Interventions: JTT-252 or Placebo, JTT-252; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Overland Park, Kansas • Austin, Texas

Conditions: Acne Vulgaris
Interventions: Imsidolimab, Placebo; Drug · Biological
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Hot Springs, Arkansas • Fountain Valley, California • Sherman Oaks, California + 9 more

Conditions: Friedreich's Ataxia
Interventions: VP 20629, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 2 more

Conditions: Influenza, Influenza -Like Illness
Interventions: Norketotifen, Placebo; Drug
Lead sponsor: Emergo Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • DeBary, Florida + 15 more

Conditions: Healthy
Interventions: Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 329 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Sjogren-Larsson Syndrome
Interventions: ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 3 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: New Haven, Connecticut • Omaha, Nebraska

Conditions: Ventral Hernia
Interventions: AGN-151607-DP, Placebo for AGN-151607-DP; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 13
States / cities: Riverside, California • Jacksonville, Florida • Miami, Florida + 10 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Questionnaires, Fit Bit; Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Differentiated Thyroid Cancer (DTC)
Interventions: Dabrafenib, Trametinib, Trametinib Placebo, Dabrafenib placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: Arthralgia, Bunion, Hallux Valgus, Pain
Interventions: Tapentadol (CG5503), oxycodone, placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 901 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 7
States / cities: Glendale, California • Pasadena, Maryland • Austin, Texas + 4 more

Conditions: Adolescent Lupus Nephritis, Pediatric Lupus Nephritis
Interventions: Voclosporin, Placebo Oral Capsule; Drug
Lead sponsor: Aurinia Pharmaceuticals Inc.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Rheumatoid Arthritis (RA)
Interventions: LY4213663, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: Anniston, Alabama • Phoenix, Arizona • Clearwater, Florida + 6 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: GFF MDI (PT003), FF MDI (PT005), GP MDI (PT001), Placebo MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 1,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 44
States / cities: Andalusia, Alabama • Birmingham, Alabama • Foley, Alabama + 37 more

Conditions: Androgenetic Alopecia
Interventions: minoxidil; Drug
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 15 Years to 49 Years · Male only
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 15
States / cities: La Jolla, California • San Francisco, California • Vallejo, California + 12 more

Conditions: Chronic Pain
Interventions: Kindolor Tosylate, Placebo; Drug
Lead sponsor: Lohocla Research Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Chronic Hepatitis C
Interventions: Daclatasvir, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Anaheim, California • Cypress, California • New Haven, Connecticut + 4 more

Conditions: Pterygium
Interventions: CBT-001, Vehicle; Drug
Lead sponsor: Cloudbreak Therapeutics, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 20
States / cities: Dothan, Alabama • Sun City, Arizona • Bakersfield, California + 16 more

Conditions: Tendinopathy
Interventions: secukinumab, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Phoenix, Arizona • La Mesa, California • Clearwater, Florida + 2 more

Conditions: Healthy Adults
Interventions: Nasal Spray; Other
Lead sponsor: Akita Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Intestinal Obstruction, Digestive System Surgical Procedures
Interventions: Seprafilm Bioresorbable Membrane; Device
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 16
States / cities: Scottsdale, Arizona • Los Angeles, California • Torrence, California + 11 more

Conditions: Cystic Fibrosis
Interventions: GS-5737, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy Volunteers, Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 150 µg, Indacaterol 300 µg, Indacaterol 600 µg, Placebo, Placebo/moxifloxacin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 404 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Suicide
Interventions: Suicide Risk Screening, Safety Planning, Care transition facilitation, A Lean Implementation Strategy; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 12 Years and older
Enrollment: 493,756 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Postoperative Pain
Interventions: HTX-011B, Placebo, HTX-011A, HTX-002, Bupivicaine HCl; Drug
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 277 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Phoenix, Arizona • Pasadena, California • Pasadena, Maryland + 3 more

Search by objective public record fields.

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia

Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair

HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis

A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss

A Study to Test the Effects of Kindolor at Different Doses in Healthy Adults

A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy

Feasibility, Acceptability, and Safety of a Drug-Free Nasal Spray in Frontline Healthcare Workers

Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery

Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF

Cardiac Safety of Indacaterol

A System of Safety (SOS)

Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery